Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of KPI-121 1.0% Ophthalmic Suspension in Subjects With Postsurgical Inflammation and Pain
Conditions
Interventions
KPI-121 1% Ophthalmic Suspension dosed BID
Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Locations
35
United States
Arizona Eye Center
Chandler, Arizona, United States
Cornea and Cataract Consultants of CA
Phoenix, Arizona, United States
Sall Research Medical Center
Artesia, California, United States
Orange County Ophthalmology
Garden Grove, California, United States
Lugene Eye Institute
Glendale, California, United States
Inland Eye Specialists
Hemet, California, United States
Start Date
June 1, 2016
Primary Completion Date
March 1, 2017
Completion Date
March 1, 2017
Last Updated
December 16, 2020
Lead Sponsor
Kala Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions